{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:27:04Z","timestamp":1790368024159,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mucopolysaccharidosis (MPS) and glycoproteinosis are 2 groups of heterogenous lysosomal storage disorders (LSDs) caused by defective degradation of glycosaminoglycans (GAGs) and glycoproteins, respectively. Oligosaccharides and glycoamino acids have been recognized as biomarkers for MPS and glycoproteinosis. Given that both groups of LSDs have overlapping clinical features, a multiplexed assay capable of unambiguous subtyping is desired for accurate diagnosis, and potentially for severity stratification and treatment monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Urinary oligosaccharides were derivatized with 3-methyl-1-phenyl-2-pyrazoline-5-one (PMP) and analyzed by ultra-performance liquid chromatography\u2013tandem mass spectrometry (UPLC-MS\/MS) together with the underivatized glycoamino acids. Novel biomarkers were identified with a semi-targeted approach with precursor mass scanning, the fragmentation pattern (if applicable), and the biochemical basis of the condition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A UPLC-MS\/MS analysis with improved chromatographic separation was developed. Novel biomarkers for MPS-IIIA, IIIB, IIIC, and VII were identified and validated. A total of 28 oligosaccharides, 2 glycoamino acids, and 2 ratios were selected as key diagnostic biomarkers. Validation studies including linearity, lower limit of quantitation (LLOQ), and precision were carried out with the assay performance meeting the required criteria. Age-specific reference ranges were collected. In the 76 untreated patients, unambiguous diagnosis was achieved with 100% sensitivity and specificity. Additionally, the levels of disease-specific biomarkers were substantially reduced in the treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A multiplexed UPLC-MS\/MS assay for urinary oligosaccharides and glycoamino acids measurement was developed and validated. The assay is suitable for the accurate diagnosis and subtyping of MPS and glycoproteinosis, and potentially for severity stratification and monitoring response to treatment.<\/jats:p><\/jats:sec>","DOI":"10.1093\/clinchem\/hvae043","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T09:41:04Z","timestamp":1712742064000},"page":"865-877","source":"Crossref","is-referenced-by-count":7,"title":["Ultra-Performance Liquid Chromatography\u2013Tandem Mass Spectrometry Analysis of Urinary Oligosaccharides and Glycoamino Acids for the Diagnosis of Mucopolysaccharidosis and Glycoproteinosis"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-307X","authenticated-orcid":false,"given":"Parith","family":"Wongkittichote","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia , Philadelphia, PA , United States"},{"name":"Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artis","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"King","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zackary M","family":"Herbst","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Washington , Seattle, WA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-5842","authenticated-orcid":false,"given":"Zhimei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Statistics and Data Science, The Wharton School of the University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Gelb","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Washington , Seattle, WA , United States"},{"name":"Department of Biochemistry, University of Washington , Seattle, WA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-5193","authenticated-orcid":false,"given":"Xinying","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia , Philadelphia, PA , United States"},{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"2024060223532556200_hvae043-B1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024060223532556200_hvae043-B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/glycob\/cwh049","article-title":"Glycosaminoglycan degradation fragments in mucopolysaccharidosis I","volume":"14","author":"Fuller","year":"2004","journal-title":"Glycobiology"},{"key":"2024060223532556200_hvae043-B3","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3390\/biom11121775","article-title":"Therapeutic approaches in lysosomal storage diseases","volume":"11","author":"Fern\u00e1ndez-Pereira","year":"2021","journal-title":"Biomolecules"},{"key":"2024060223532556200_hvae043-B4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/biom11040611","article-title":"Gene therapy for lysosomal storage disorders: ongoing studies and clinical development","volume":"11","author":"Massaro","year":"2021","journal-title":"Biomolecules"},{"key":"2024060223532556200_hvae043-B5","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cells9081838","article-title":"Mucopolysaccharidosis type I: a review of the natural history and molecular pathology","volume":"9","author":"Hampe","year":"2020","journal-title":"Cells"},{"key":"2024060223532556200_hvae043-B6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s10038-020-0744-8","article-title":"Newborn screening of mucopolysaccharidoses: past, present, and future","volume":"65","author":"Arunkumar","year":"2020","journal-title":"J Hum Genet"},{"key":"2024060223532556200_hvae043-B7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1258\/000456307780945688","article-title":"Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses-an evaluation","volume":"44","author":"Gray","year":"2007","journal-title":"Ann Clin Biochem"},{"key":"2024060223532556200_hvae043-B8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2010.09.003","article-title":"Efficient analysis of urinary glycosaminoglycans by LC-MS\/MS in mucopolysaccharidoses type I, II and VI","volume":"102","author":"Auray-Blais","year":"2011","journal-title":"Mol Genet Metab"},{"key":"2024060223532556200_hvae043-B9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2007.05.016","article-title":"Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography\/turbo ionspray ionization tandem mass spectrometry","volume":"368","author":"Oguma","year":"2007","journal-title":"Anal Biochem"},{"key":"2024060223532556200_hvae043-B10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1203\/01.PDR.0000141987.69757.DD","article-title":"Disease-specific markers for the mucopolysaccharidoses","volume":"56","author":"Fuller","year":"2004","journal-title":"Pediatr Res"},{"key":"2024060223532556200_hvae043-B11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41436-018-0136-z","article-title":"Disease and subtype specific signatures enable precise diagnosis of the mucopolysaccharidoses","volume":"21","author":"Saville","year":"2019","journal-title":"Genet Med"},{"key":"2024060223532556200_hvae043-B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ymgme.2021.08.006","article-title":"Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry","volume":"134","author":"Mak","year":"2021","journal-title":"Mol Genet Metab"},{"key":"2024060223532556200_hvae043-B13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non\u2013reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat Chem Biol"},{"key":"2024060223532556200_hvae043-B14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/glycob\/cwz109","article-title":"Characterization of disease-specific chondroitin sulfate non-reducing end accumulation in mucopolysaccharidosis IVA","volume":"30","author":"Lawrence","year":"2020","journal-title":"Glycobiology"},{"key":"2024060223532556200_hvae043-B15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1373\/clinchem.2018.289645","article-title":"UPLC-MS\/MS analysis of urinary free oligosaccharides for lysosomal storage diseases: diagnosis and potential treatment monitoring","volume":"64","author":"Huang","year":"2018","journal-title":"Clin Chem"},{"key":"2024060223532556200_hvae043-B16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1373\/clinchem.2012.201053","article-title":"Oligosaccharide analysis in urine by maldi-tof mass spectrometry for the diagnosis of lysosomal storage diseases","volume":"59","author":"Xia","year":"2013","journal-title":"Clin Chem"},{"key":"2024060223532556200_hvae043-B17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ab.2005.06.042","article-title":"Profiling oligosaccharidurias by electrospray tandem mass spectrometry: quantifying reducing oligosaccharides","volume":"345","author":"Ramsay","year":"2005","journal-title":"Anal Biochem"},{"key":"2024060223532556200_hvae043-B18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/(SICI)1096-9888(199905)34:5<502::AID-JMS800>3.0.CO;2-G","article-title":"Electrospray ionization mass spectrometry of 1-phenyl-3-methyl-5-pyrazolone derivatives of neutral and N-acetylated oligosaccharides","volume":"34","author":"Shen","year":"1999","journal-title":"J Mass Spectrom"},{"key":"2024060223532556200_hvae043-B19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/8904_2014_366","article-title":"Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset pompe disease identified by newborn screening","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Rep"},{"key":"2024060223532556200_hvae043-B20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jimd.12688","article-title":"Biochemical signatures of disease severity in multiple sulfatase deficiency","volume":"47","author":"Adang","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"2024060223532556200_hvae043-B21","doi-asserted-by":"crossref","first-page":"100524","DOI":"10.1016\/j.ymgmr.2019.100524","article-title":"Characterization of glycan substrates accumulating in GM1 gangliosidosis","volume":"21","author":"Lawrence","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"2024060223532556200_hvae043-B22","doi-asserted-by":"crossref","first-page":"104627","DOI":"10.1016\/j.ebiom.2023.104627","article-title":"A pentasaccharide for monitoring pharmacodynamic response to gene therapy in GM1 gangliosidosis","volume":"92","author":"Kell","year":"2023","journal-title":"EBioMedicine"},{"key":"2024060223532556200_hvae043-B23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ymgme.2019.10.009","article-title":"Multiplex testing for the screening of lysosomal storage disease in urine: sulfatides and glycosaminoglycan profiles in 40 cases of sulfatiduria","volume":"129","author":"Pino","year":"2020","journal-title":"Mol Genet Metab"},{"key":"2024060223532556200_hvae043-B24","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.ymgmr.2021.100747","article-title":"Placental pathology in an unsuspected case of mucolipidosis type II with secondary hyperparathyroidism in a premature infant","volume":"27","author":"Wongkittichote","year":"2021","journal-title":"Mol Genet Metab Rep"},{"key":"2024060223532556200_hvae043-B25","doi-asserted-by":"crossref","first-page":"100978","DOI":"10.1016\/j.ymgmr.2023.100978","article-title":"Multiplex tandem mass spectrometry enzymatic activity assay for the screening and diagnosis of mucolipidosis type II and III","volume":"35","author":"Hong","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"2024060223532556200_hvae043-B26","doi-asserted-by":"crossref","first-page":"100583","DOI":"10.1016\/j.ymgmr.2020.100583","article-title":"Urine glucose tetrasaccharide: a good biomarker for glycogenoses type II and III? A study of the French cohort","volume":"23","author":"Piraud","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"2024060223532556200_hvae043-B27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jimd.12588","article-title":"MOGS-CDG: quantitative analysis of the diagnostic Glc(3) Man tetrasaccharide and clinical spectrum of six new cases","volume":"46","author":"Post","year":"2023","journal-title":"J Inherit Metab Dis"},{"key":"2024060223532556200_hvae043-B28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jb\/mvab111","article-title":"GlcNAc-Asn is a biomarker for NGLY1 deficiency","volume":"171","author":"Mueller","year":"2022","journal-title":"J Biochem"},{"key":"2024060223532556200_hvae043-B29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ymgme.2018.03.002","article-title":"Urine oligosaccharide screening by MALDI-TOF for the identification of NGLY1 deficiency","volume":"124","author":"Hall","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2024060223532556200_hvae043-B30","doi-asserted-by":"crossref","first-page":"107632","DOI":"10.1016\/j.ymgme.2023.107632","article-title":"Endogenous, non-reducing end glycosaminoglycan biomarkers are superior to internal disaccharide glycosaminoglycan biomarkers for newborn screening of mucopolysaccharidoses and GM1 gangliosidosis","volume":"140","author":"Herbst","year":"2023","journal-title":"Mol Genet Metab"},{"key":"2024060223532556200_hvae043-B31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ijns8010009","article-title":"Evaluation of two methods for quantification of glycosaminoglycan biomarkers in newborn dried blood spots from patients with severe and attenuated mucopolysaccharidosis type II","volume":"8","author":"Herbst","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"2024060223532556200_hvae043-B32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/ijns6030069","article-title":"Evaluation of multiple methods for quantification of glycosaminoglycan biomarkers in newborn dried blood spots from patients with severe and attenuated mucopolysaccharidosis-I","volume":"6","author":"Herbst","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"2024060223532556200_hvae043-B33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jprot.2016.08.012","article-title":"Quantitative O-glycomics based on improvement of the one-pot method for nonreductive O-glycan release and simultaneous stable isotope labeling with 1-(d0\/d5)phenyl-3-methyl-5-pyrazolone followed by mass spectrometric analysis","volume":"150","author":"Wang","year":"2017","journal-title":"J Proteomics"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/6\/865\/58036697\/hvae043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/6\/865\/58036697\/hvae043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:16:43Z","timestamp":1731586603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/70\/6\/865\/7643213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvae043","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,10]]}}}